Glaukos Corp
Change company Symbol lookup
Select an option...
GKOS Glaukos Corp
FIXX Homology Medicines Inc
APAM Artisan Partners Asset Management Inc
TQQQ ProShares UltraPro QQQ
AVCT American Virtual Cloud Technologies Inc
LITM Snow Lake Resources Ltd
SJ Scienjoy Holding Corp
PBTS Powerbridge Technologies Co Ltd
DRTT DIRTT Environmental Solutions Ltd
LVTX LAVA Therapeutics NV
Go

Health Care : Health Care Equipment & Supplies | Small Cap Blend
Company profile

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. It is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants that are designed to elute pharmaceuticals.

Closing Price
$50.25
Day's Change
-0.14 (-0.28%)
Bid
--
Ask
--
B/A Size
--
Day's High
51.39
Day's Low
49.69
Volume
(Light)
Volume:
382,169

10-day average volume:
572,080
382,169

Display:

Providers:

UpdateCancel
4 providers
July 12, 2022
Glaukos stock price target raised to $60 from $40 at Stifel Nicolaus

(END) Dow Jones Newswires July 12, 2022 07:28 ET (11:28 GMT) (MarketWatch)

Glaukos upgraded to buy from hold at Stifel Nicolaus

(END) Dow Jones Newswires July 12, 2022 07:28 ET (11:28 GMT) (MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.